Celltrion Pharm, Inc. (068760.KQ)
KRW 61300.0
(-3.01%)
KRW 61300.0
(-3.01%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 116.95 Billion KRW | 4.75% |
| 2022 | 111.65 Billion KRW | -5.57% |
| 2021 | 118.24 Billion KRW | 64.93% |
| 2020 | 71.69 Billion KRW | 17.9% |
| 2019 | 60.8 Billion KRW | 54.85% |
| 2018 | 39.26 Billion KRW | -31.15% |
| 2017 | 57.03 Billion KRW | 40.15% |
| 2016 | 40.69 Billion KRW | -13.45% |
| 2015 | 47.01 Billion KRW | 108825.8% |
| 2014 | 43.16 Million KRW | 21.52% |
| 2013 | 35.52 Million KRW | 12.07% |
| 2012 | 31.69 Million KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 22.99 Billion KRW | -10.69% |
| 2024 Q2 | 28.59 Billion KRW | 24.33% |
| 2023 Q3 | 28.52 Billion KRW | -18.59% |
| 2023 Q4 | 25.74 Billion KRW | -9.75% |
| 2023 FY | 116.95 Billion KRW | 4.75% |
| 2023 Q1 | 27.63 Billion KRW | 14.48% |
| 2023 Q2 | 35.04 Billion KRW | 26.79% |
| 2022 FY | 111.65 Billion KRW | -5.57% |
| 2022 Q4 | 24.14 Billion KRW | -28.26% |
| 2022 Q1 | 25.03 Billion KRW | -20.28% |
| 2022 Q3 | 33.65 Billion KRW | 16.78% |
| 2022 Q2 | 28.81 Billion KRW | 15.09% |
| 2021 Q3 | 29.72 Billion KRW | -9.01% |
| 2021 Q4 | 31.4 Billion KRW | 5.67% |
| 2021 Q2 | 32.66 Billion KRW | 33.65% |
| 2021 Q1 | 24.44 Billion KRW | 110680.35% |
| 2021 FY | 118.24 Billion KRW | 64.93% |
| 2020 Q3 | 17.41 Million KRW | 4.05% |
| 2020 FY | 71.69 Billion KRW | 17.9% |
| 2020 Q4 | 22.06 Million KRW | 26.69% |
| 2020 Q2 | 16.73 Million KRW | 0.14% |
| 2020 Q1 | 16.71 Million KRW | -11.54% |
| 2019 FY | 60.8 Billion KRW | 54.85% |
| 2019 Q3 | 15.74 Million KRW | -0.91% |
| 2019 Q1 | 11.71 Million KRW | -14.75% |
| 2019 Q4 | 18.89 Million KRW | 20.04% |
| 2019 Q2 | 15.88 Million KRW | 35.54% |
| 2018 Q2 | 9.21 Million KRW | -5.17% |
| 2018 FY | 39.26 Billion KRW | -31.15% |
| 2018 Q1 | 9.71 Million KRW | -41.77% |
| 2018 Q4 | 13.74 Million KRW | 78.5% |
| 2018 Q3 | 7.7 Million KRW | -16.39% |
| 2017 Q1 | 8.36 Million KRW | 102.47% |
| 2017 Q2 | 17.45 Million KRW | 108.59% |
| 2017 FY | 57.03 Billion KRW | 40.15% |
| 2017 Q4 | 16.68 Million KRW | 7.05% |
| 2017 Q3 | 15.58 Million KRW | -10.72% |
| 2016 Q3 | 12.75 Million KRW | -6.86% |
| 2016 FY | 40.69 Billion KRW | -13.45% |
| 2016 Q1 | 11.28 Million KRW | -3.37% |
| 2016 Q2 | 13.69 Million KRW | 21.37% |
| 2016 Q4 | 4.13 Million KRW | -67.59% |
| 2015 Q3 | 12.4 Million KRW | -3.53% |
| 2015 Q2 | 12.86 Million KRW | 18.41% |
| 2015 Q1 | 10.86 Million KRW | 5.03% |
| 2015 FY | 47.01 Billion KRW | 108825.8% |
| 2015 Q4 | 11.67 Million KRW | -5.9% |
| 2014 Q3 | 13.12 Million KRW | 8.45% |
| 2014 FY | 43.16 Million KRW | 21.52% |
| 2014 Q4 | 10.34 Million KRW | -21.18% |
| 2014 Q2 | 12.09 Million KRW | 59.08% |
| 2014 Q1 | 7.6 Million KRW | -19.59% |
| 2013 Q3 | 8.95 Million KRW | 5.43% |
| 2013 FY | 35.52 Million KRW | 12.07% |
| 2013 Q1 | 8.61 Million KRW | -8.44% |
| 2013 Q4 | 9.45 Million KRW | 5.64% |
| 2013 Q2 | 8.49 Million KRW | -1.48% |
| 2012 Q4 | 9.41 Million KRW | 0.0% |
| 2012 FY | 31.69 Million KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 82.98 Billion KRW | -40.941% |
| CMG Pharmaceutical Co., Ltd. | 43.7 Billion KRW | -167.626% |
| Huons Global Co., Ltd. | 417.8 Billion KRW | 72.006% |
| DongKook Pharmaceutical Co., Ltd. | 405.04 Billion KRW | 71.124% |
| Enzychem Lifesciences Corporation | 3.29 Billion KRW | -3451.242% |
| Humedix Co., Ltd. | 68.04 Billion KRW | -71.887% |
| Boditech Med Inc. | 76.7 Billion KRW | -52.48% |
| EuBiologics Co., Ltd. | 32.65 Billion KRW | -258.124% |
| FutureChem Co.,Ltd | 758.27 Million KRW | -15324.547% |
| Huons Co., Ltd. | 285.93 Billion KRW | 59.096% |
| BNC Korea Co., Ltd. | 31.97 Billion KRW | -265.75% |
| AptaBio Therapeutics Inc. | 78.49 Million KRW | -148895.682% |